Skip to main content
Home
Drug Metabolic Roadmap (2024 update)
★
Drug Metabolic Roadmap
★
Drug Metabolite
★
Metabolic Reaction
DME Interactome
Microbiome-DME Interaction
Host Protein-DME Interaction
Xenobiotics-DME Interaction
Download
Help
Drug Information
Drug General Information
Drug ID
D01ZYY
Former ID
DIB011553
Drug Name
Intranasal apomorphine
Indication
Sexual dysfunction [ICD9: 302.7; ICD10:F52]
Phase 2
[
527086
]
Company
Nastech Pharmaceutical
Target and Pathway
Target(s)
D(2) dopamine receptor
Target Info
Agonist
[
534197
]
D(4) dopamine receptor
Target Info
Agonist
[
534578
]
Dopamine D1 receptor
Target Info
Agonist
[
534197
]
KEGG Pathway
Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04020:Calcium signaling pathway
Amphetamine addiction
Morphine addiction
Alcoholism
PANTHER Pathway
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Nicotine pharmacodynamics pathwayP05912:Dopamine receptor mediated signaling pathway
PathWhiz Pathway
Dopamine Activation of Neurological Reward System
Reactome
Dopamine receptors
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (s) signalling events
WikiPathways
Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
Nicotine Activity on Dopaminergic Neurons
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
References
Ref 527086
Intranasal apomorphine. Nastech Pharmaceutical. IDrugs. 2004 May;7(5):483-8.
Ref 534197
Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Nov;19(7):1147-54.
Ref 534578
Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology (Berl). 1998 Jan;135(2):194-200.
If you find any error in data or bug in web service, please kindly report it to
Dr. Yin
and
Dr. Li
.